adalimumab-atto (Amjevita) vs infliximab-axxq (Avsola)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-atto (Amjevita)
Marketed by Amgen
NCT01970475 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)
Result source: NCT01970475
infliximab-axxq (Avsola)
Marketed by Amgen
NCT02937701 · Phase 3 · completed
The single primary endpoint was ACR20 response at week 22, tested for equivalence with a margin of -15% to 15%. The prespecified analysis gave a response difference of 9.37% with a 90% confidence interval of 2.67% to 15.96%, so the upper bound passed the margin and equivalence was not shown, while non-inferiority held; only a post hoc covariate-adjusted analysis fell inside the margin. The primary result is therefore unclear. Figures are from the ClinicalTrials.gov posted results.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22 (Baseline and week 22): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22 (Baseline and week 22): ABP 710 68.1 percentage of participants (95% CI 62.63 to 73.57) | Infliximab 59.1 percentage of participants (95% CI 53.37 to 64.91) (unclear)
Result source: NCT02937701
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-atto (Amjevita) | infliximab-axxq (Avsola) |
|---|---|---|
| ACR20 | 74.6% vs 72.4%vs AdalimumabNCT019704752 other results
| —Not reported |
| ACR50 | 49.2% vs 52%vs AdalimumabNCT01970475 | —Not reported |
| ACR70 | 26% vs 22.9%vs AdalimumabNCT01970475 | —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-atto (Amjevita)
- 74.6% vs 72.4%vs AdalimumabNCT01970475
2 other results
- 63.5% vs 62.5% NCT01970475
- 35.4% vs 24.5% NCT01970475
- infliximab-axxq (Avsola)
- —Not reported
ACR50
- adalimumab-atto (Amjevita)
- 49.2% vs 52%vs AdalimumabNCT01970475
- infliximab-axxq (Avsola)
- —Not reported
ACR70
- adalimumab-atto (Amjevita)
- 26% vs 22.9%vs AdalimumabNCT01970475
- infliximab-axxq (Avsola)
- —Not reported
DAS28-CRP remission
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-axxq (Avsola)
- —Not reported
HAQ-DI, change
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-axxq (Avsola)
- —Not reported
Modified Sharp score, change
- adalimumab-atto (Amjevita)
- —Not reported
- infliximab-axxq (Avsola)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-axxq (Avsola): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-atto (Amjevita): 4 of 4 rows · infliximab-axxq (Avsola): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-atto (Amjevita) |
|---|---|
| Dropout rate | 8%a NCT01970475 · Phase 3 |
| Discontinued due to AEs | 2.7%a NCT01970475 · Phase 3 |
| Serious AEs | 3.8%a NCT01970475 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-atto (Amjevita)
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · infliximab-axxq (Avsola)'s landscape